REN
AL C
ARE
SOLACEA™
HIGH FLUX, ATA™ FIBER DIALYZER
2
SOLACEA™HIGH F LU X , ATA™ F IBER DI A LY ZER
IMAGINEHistorically, the first membranes used for the hemodialysis were cellulose based. Even today, modified cellulose membranes, cellulose triacetate membranes, are remaining the fibers of choice for patients with hypersensitivity reactions against synthetic fibers.Nowadays, however, synthetic fibers have become the preferred membrane. This switch is empowered by the demand of the new dialysis treatments. High volume hemodiafiltration (HDF), only partially possible with cellulose based membranes, is made achievable by the characteristics of a synthetic membrane, like the asymmetric fibers and chemical composition. The improvement of the dialysis treatments with synthetic fibers is however associated with an increased risk of hypersensitivity reactions.
For these reasons, healthcare providers and patients remain divided between these two different types of dialyzers, due to the unavailability of a product which combines the strengths of both membranes.
Till today.
3
UNIQUE FEATURES
Now imagine, a technology able to combine all the advantages typical of the synthetic membranes in terms of treatment, with the benefits of the natural fibers in terms of reduced allergic reactions. A product able to cover the entire range of therapies from standard hemodialysis (HD) up to high volume HDF, reducing at the same time the needs for anticoagulants and limiting the risk of hypersensitivity reactions associated with a synthetic membrane.
This product finally exists: it’s the new SOLACEA™, brought to you by Nipro.
ATA™ (ASYMMETRIC TRIACETATE)SOLACEA allows outstanding performance thanks to its asymmetric structure, yet keeping all the advantages of semi-natural fibers.
SMOOTH MEMBRANE SURFACEReduced membrane fouling, minimizes clogging of the pores and generates a limited TMP build-up.
FULL RANGE OF APPLICATIONS The SOLACEA can perform the ‘simple’ HD treatments up to the ‘advanced’ high volume ‘convective’ HDF.
BPA - FREESOLACEA is free of bisphenol-A, a proven endocrine disruptor and associated with the increased risk of residual kidney function loss.
GAMMA STERILIZEDSterilized by low dose gamma ray. This eliminates the use of ethylene oxide or inline steam with associated extra handling for packaging.
4
SOLACEA features an ATA membrane made by a state of the art spinning technique for dialyzer fibers. This results into a thin membrane that, due to its asymmetric structure, can withstand high volume throughput. Its uniform pore distribution on the inner membrane safeguards high clearance of middle size molecules and low albumin loss.
CUTTING-EDGE MEMBRANE TECHNOLOGY
ASYMMETRIC TRIACETATE MEMBRANE
Inner surface (x10.000)
Smooth membrane surface with optimized pore distribution
Membrane cross section (x 5000) Outer surface (x10.000)
Asymmetric supporting layer reduces pressure build-up
HELIXONE™ (PS/PVP) SOLACEA (ATA)
Ra = 11nm | RMS = 15nm Ra = 3.8nm | RMS = 5.0nm
SMOOTH MEMBRANE SURFACESOLACEA’s smooth surface reduces membrane fouling. This decreases pore clogging and the associated performance drop at the beginning of the dialysis session.
Atomic force microscopic (AMF) image. Ra: average roughness; RMS: square-mean roughness
5
Effective high volume HDF treatments depend on fibers that can withstand high fluid transferal over the membrane and keeping transmembrane pressure (TMP) at a minimum. SOLACEA features an asymmetric membrane with a smooth surface, which limits TMP buildup, making the membrane ideal for treatments that require high volume fluid subtraction.
INNOVATIVE DIALYZER FOR HIGH VOLUME HDF
EFFECTIVE HIGH VOLUME HDF KEEPING TMP AT MINIMUMAs demonstrated in the graph, the SOLACEA has very low TMP values and the TMP buildup is very low in the first 30 min of HDF treatment.
50
70
90
110
130
150
170
190
210
230
250
0:00 1:26 2:52 4:19 5:45
TMP
(mm
Hg
)
Time
FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80
TMP*
EXCELLENT PERFORMANCE WITH LIMITED ALBUMIN LOSS As demonstrated in the graph, the SOLACEA has an excellent performance in high volume HDF, as proven by the removal rate of middle size molecules, as measured by beta-2-microglobulin (β2-M) and myoglobin, with limited loss of albumin. In both cases, the SOLACEA shows low albumin loss, with comparable removal rate for β2-M and high removal rate for myoglobin.
β2-M
rem
oval
rat
e (%
)
Albumin loss (mg/session)
Myo
glob
in r
emov
al r
ate
(%)
Albumin loss (mg/session)
0
20
40
60
80
100
0 500 1000 1500 2000 2500 30000
20
40
60
80
100
0 500 1000 1500 2000 2500 3000
FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80 FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80
β2-M
rem
oval
rat
e (%
)
Albumin loss (mg/session)
Myo
glob
in r
emov
al r
ate
(%)
Albumin loss (mg/session)
0
20
40
60
80
100
0 500 1000 1500 2000 2500 30000
20
40
60
80
100
0 500 1000 1500 2000 2500 3000
FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80 FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80
β2-M
rem
oval
rat
e (%
)
Albumin loss (mg/session)
Myo
glob
in r
emov
al r
ate
(%)
Albumin loss (mg/session)
0
20
40
60
80
100
0 500 1000 1500 2000 2500 30000
20
40
60
80
100
0 500 1000 1500 2000 2500 3000
FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80 FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80
β2-M
rem
oval
rat
e (%
)
Albumin loss (mg/session)
Myo
glob
in r
emov
al r
ate
(%)
Albumin loss (mg/session)
0
20
40
60
80
100
0 500 1000 1500 2000 2500 30000
20
40
60
80
100
0 500 1000 1500 2000 2500 3000
FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80 FX CorDiax 800SOLACEA-19H Polyflux® 210H FX 80
β2-M removal and albumin loss** Myoglobin removal and albumin loss**
* Qb 350mL/min, Qd 600mL/min, Qs 85mL/min; ** Qb 350mL/min, Qd 600mL/min, Qs 100mL/min. Clinical data from in vivo experiments performed by BioArtProducts, Rostock, Germany in 2015.
6
BIOCOMPATIBLE MEMBRANESOLACEA has excellent thrombogenicity and biocompatibility characteristics.
SOLACEA-19H FX CorDiax 800 FX80 Polyflux® 210H
0
2
4
6
8
10
0 50 100 150 200 250
Gpt
/L
min
0,0
0,5
1,0
1,5
2,0
0 50 100 150 200 250ng
/mL
min
0
30
60
90
120
150
180
0 50 100 150 200 250
Gpt
/L
minSOLACEA-19H FX CorDiax 800 FX80 Polyflux® 210H
0
2
4
6
8
10
0 50 100 150 200 250
Gpt
/L
min
0,0
0,5
1,0
1,5
2,0
0 50 100 150 200 250
ng/m
Lmin
0
30
60
90
120
150
180
0 50 100 150 200 250
Gpt
/L
min
SOLACEA-19H FX CorDiax 800 FX80 Polyflux® 210H
0
2
4
6
8
10
0 50 100 150 200 250
Gpt
/L
min
0,0
0,5
1,0
1,5
2,0
0 50 100 150 200 250
ng/m
L
min
0
30
60
90
120
150
180
0 50 100 150 200 250
Gpt
/L
minSOLACEA-19H FX CorDiax 800 FX80 Polyflux® 210H
0
2
4
6
8
10
0 50 100 150 200 250G
pt/L
min
0,0
0,5
1,0
1,5
2,0
0 50 100 150 200 250
ng/m
L
min
0
30
60
90
120
150
180
0 50 100 150 200 250
Gpt
/L
min
C5a generation*White blood cell count*
In the first 30 min of the HD treatment the white blood cell count shows a small drop. The increase of complement activation, measured by C5a, is in line with synthetic membranes.
When we look at the platelet count in the first 30 min, we see that there is only a very minor drop, after which it returns to normal levels.
SOLACEA-19H FX CorDiax 800 FX80 Polyflux® 210H
0
2
4
6
8
10
0 50 100 150 200 250
Gpt
/L
min
0,0
0,5
1,0
1,5
2,0
0 50 100 150 200 250
ng/m
L
min
0
30
60
90
120
150
180
0 50 100 150 200 250
Gpt
/L
min
SOLACEA-19H FX CorDiax 800 FX80 Polyflux® 210H
0
2
4
6
8
10
0 50 100 150 200 250
Gpt
/L
min
0,0
0,5
1,0
1,5
2,0
0 50 100 150 200 250
ng/m
L
min
0
30
60
90
120
150
180
0 50 100 150 200 250
Gpt
/L
min
Platelet count*
* Qb 350ml/min, Qd 600ml/min, Qs 0mL/min. Clinical data from in vivo experiments performed by BioArtProducts, Rostock, Germany in 2015.
PERFORMANCEClearance (ml/min)(5) Qb/ Qd (ml/min) 15H 17H 19H 21H 25H
Urea
200/500 196 197 198 199 199
300/500 266 274 278 283 289
400/500 312 323 332 340 352
Creatinine
200/500 191 193 195 198 198
300/500 251 260 267 273 279
400/500 289 301 311 320 331
Phosphate
200/500 185 188 190 194 196
300/500 236 246 254 262 271
400/500 268 282 293 301 318
Vitamin B12
200/500 150 158 164 169 176
300/500 178 189 199 208 220
400/500 193 208 219 230 246
Ultrafiltration CoefficientKUF [mL/hr/mmHg]2 61 69 72 76 87
Sieving Coefficient3
Vitamin B12 1,00
Inulin 1,00
ϐ2-microglobulin 0,85
Myoglobin 0,80
Albumin 0,013
SPECIFICATIONSEffective surface area (m2) 1,5 1,7 1,9 2,1 2,5
Priming volume (ml) 86 98 108 118 139
Effective length (mm) 227 233 245 254 280
Inner Diameter (μm) 200 200 200 200 200
Membrane thickness (μm) 25 25 25 25 25
Maximum TMP (mmHg) 500 500 500 500 500
Pressure DropQb/Qd [mL/min] 200/500 200/500 200/500 200/500 200/500
Blood/Dialysate [mmHg] 51/16 47/18 47/16 45/15 43/8
Material
Membrane ATA™
Housing and Header Polypropylene
Potting compound Polyurethane
Sterilization method Dry gamma
Package 24 pcs/box
In vitro testing conditions (ISO 8637)1. Clearance: Qf 0mL/min2. KUF: bovine blood (Hct 32+- 3%, Protein 60g/L, 37°C), Qb 200mL/min3. SC: Qb 300 mL/min, Qf 60mL/min
SOLACEA™ - H HIGH FLUX
7
NIPRO MEDICAL AUSTRIA GMBH : Divischgasse 4, 1210 Wien, AUSTRIA | T: +43 1 532 23 14 | F: +43 1 532 23 14 89NIPRO EUROPE - EGYPT : Nile City Towers, 22nd Floor, North Tower, Nile City, Towers, Cornich El Nile, 11624 Ramelt Beaulac, Cairo, EGYPTNIPRO MEDICAL FRANCE S.A. :Biopôle Clermont-Limagne, 63360 Saint Beauzire, FRANCE | T: +33 (0)473 33 41 00 | F: +33 (0)473 33 41 09NIPRO MEDICAL GERMANY GMBH : Kokkolastrasse 5, 40882 Ratingen, GERMANY | T: +49 (0)2102 564 60 81 | F: +49 (0)2102 564 60 90NIPRO MEDICAL EUROPE NV - ITALY : Centro Direzionale Milanofiori, Strada 1 - Palazzo F1, 20090 Assago (Milano), ITALY | T: +39 (0)2 57 50 00 57 | F: +39 (0)2 57 51 81 11NIPRO MEDICAL EUROPE NV - NETHERLANDS : Verlengde Poolseweg 16, 4818 CL Breda, NETHERLANDS | T: +31 (0)76 524 50 99 | F: +31 (0)76 524 46 66NIPRO MEDICAL NIGERIA LTD. : 9 Adelabu Close, Off Toyin Street, 100271 Ikeja, Lagos State, NIGERIA | T: +234 (0)802 706 7065NIPRO MEDICAL POLAND SP. Z O.O. : Ul. Panska 73, 00-834 Warszawa, POLAND | T: +48 (0)22 31 47 155 | F: +48 (0)22 31 47 152NIPRO EUROPE - PORTUGAL : Avd. Da Liberdade 249, 1° Andar, 1205-143 Lisboa, PORTUGAL | T: +34 (0)91 878 29 21 | F: +34 (0)91 878 28 40
NIPRO MEDICAL EUROPE - RUSSIAN REPRESENTATIVE OFFICE : 12 Krasnopresnenskaya Nab., Office 1407, entrance 6, 123610 Moscow, RUSSIA | T: +7 (0)495 258 1364 | T: +7 (0)495 258 1365NIPRO MEDICAL SENEGAL S.U.A.R.L. : 27 Avenue Georges Pompidou, Dakar, SENEGALNIPRO MEDICAL D.O.O. BEOGRAD : Bastovanska 68a, 11000 Belgrade, SERBIA | T: +381 (0)11 75 15 578NIPRO MEDICAL SOUTH AFRICA (PTY) LTD : 4B Dwyka Street, Stikland Industria, Cape Town, 7530, SOUTH AFRICA | T: + 27 21 949-2635 | F: +27 21 949-2397Unit 20&21, Falcon Lane, Lanseria Business Park, Erf 805 Lanseria Corporate Estate, Pelindaba Rd.,Lanseria Ext. 26, Gauteng, SOUTH AFRICA | T: + 27 11 431 1114 / 26 | F: +27 11 431 1115NIPRO MEDICAL EUROPE NV - SPAIN : Poligono Los Frailes n° 93 y 94, Daganzo, 28814 Madrid, SPAIN | T: +34 (0)91 884 5531 | F: +34 (0)91 878 2840NIPRO MEDIKAL SAĞ.HIZ.TIC.LTD.ŞTI. : Aziziye Mah.Pilot Sok.17/4, 6540 Çankaya-Ankara, TURKEY | T: +90 (0)312 442 21 12 | F: +90 (0)312 442 21 92NIPRO MEDICAL UK LTD. : 25 Barnes Wallis Road, Segensworth East, Fareham Hampshire PO15 5TT, UNITED KINGDOM | T: +44 148 985 48 30
Nipro Medical Europe : European Headquarters, Blokhuisstraat 42, 2800 Mechelen, BelgiumT: +32 (0)15 263 500 | F: +32 (0)15 263 510 | [email protected] | www.nipro-group.com
Please contact your local representative for more information.
ENNipro Renal Care is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 28.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.
Nipro Renal Care is a global market leader with over 5 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment.
In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro Renal Care is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs.
BECAUSE EVERY LIFE DESERVES AFFORDABLE CARE
Bro-
Sola
cea
- EN
- 13
.Dec
.18Pr
oduc
ts are
cont
inuou
sly un
der r
eview
in th
e ligh
t of t
echn
ical a
dvan
ceme
nt; t
he ac
tual
spec
ifica
tions
may
there
fore b
e sub
ject t
o imp
rovem
ent o
r mod
ifica
tion w
ithou
t noti
ce. S
ome f
eatur
es an
d/or a
cces
sorie
s disp
layed
and d
escri
bed c
ould
be op
tiona
l on d
iffere
nt ma
rkets.
The i
nform
ation
pro
vided
does
not c
onsti
tute
an of
fer to
sell a
nd is
prov
ided f
or me
rely i
nform
ation
al pu
rpose
s. Im
ages
publi
shed
in th
e pres
ent d
ocum
ent a
re sh
own e
xclus
ively
for de
mo pu
rpose
s, are
repre
sent
ative
of th
e pos
sible
appli
catio
ns an
d migh
t be a
dapt
ed fo
r grap
hic ne
eds.
All ri
ghts
reserv
ed.